Small-scale Bioreactors Market Size, Share & Trends Analysis Report By Capacity, By Product (Reusable, Single-use), By End-user (CROs & CMOs, Pharma & Biopharma Companies), By Region, And Segment Forecasts, 2023 - 2030

Small-scale Bioreactors Market Size, Share & Trends Analysis Report By Capacity, By Product (Reusable, Single-use), By End-user (CROs & CMOs, Pharma & Biopharma Companies), By Region, And Segment Forecasts, 2023 - 2030

Small-scale Bioreactors Market Growth & Trends

The global small-scale bioreactors market size is expected to reach USD 5.05 billion by 2030, registering a CAGR of 14.8% over the forecast period, according to a new report by Grand View Research, Inc. The product has a high demand and the market is anticipated to grow rapidly as a result of the COVID-19 pandemic. The pandemic has increased the need for research on cell-based drug discovery and also the demand for manufacturing novel medicines and vaccines according to the size of the population. For instance, according to the World Health Organization’s 2022 report, vaccine research has accelerated to an unprecedented pace in response to the COVID-19 pandemic and approximately 11.25 billion vaccine doses had been given around the globe as of 4 April 2022.

Moreover, the use of small-scale bioprocessing systems in upstream processing, parallel processing, and experiment evaluation for bioprocess optimization is expected to drive the demand for small-scale bioreactors in process development. Revenues in the bioprocessing technology industry have increased as a result of COVID-19. Thus, the development of a SARS-CoV-2 vaccine has progressed quickly, according to all major suppliers. In addition, the demand for bioprocessing technologies had also grown as a result of a rise in vaccine R&D. For instance, in July 2020, Danaher, the parent company of Pall and Cytiva, reported a 26% increase in net income and a 19% increase in second-quarter sales. Similarly, Sartorius Stedim Biotech also has benefited from the pandemic. The company’s sales increased 18% to $1.05 billion in the first half of the year.

The desire for COVID-19 was cited by company executives as a key driver. Furthermore, the strong demand for small-scale bioreactors is being driven by the recent increase in COVID-19-related research and development between several biotech and pharmaceutical companies. Furthermore, the growth of the market during the forecast period is fueled by the rise in technical development and advancements in equipment design for bioprocessing. The sales of small-scale bioreactors are also expected to increase as a result of an increase in product launches and the expansion of product lines by several manufacturers. For instance, in October 2022, Froilabo expanded its line of temperature-controlled laboratory equipment by introducing a new collection of completely automated lab-scale bioprocessing systems.

Small-scale Bioreactors Market Report Highlights

• The reusable bioreactors segment held the largest share in 2022 owing to the higher need for reusable bioreactors in the pharmaceutical and biopharmaceutical industries for cost-effective manufacturing
• The 1L-3L capacity segment accounted for the largest revenue share in 2022 due to the wide-scale availability of bioreactors with a working volume capacity of 1L-3L in small-scale production
• The CROs & CMOs end-user segment held the largest share in 2022. Since these companies have adopted novel single-use bioreactors much more quickly than therapeutic manufacturers, they have contributed to a larger revenue share
• North America was the dominant regional market in 2022 due to the presence of several global players and growing investments from public & private organizations for proteomic and life science research in the region

Please note The report will be delivered in 3-8 business days upon order notification.